Gene symbol | tk |
Gene symbol | IL12A | Synonyms | CLMF, IL-12A, NFSK, NKSF1, P35 | Type of gene | protein-coding |
Chromosome | 3 | Map location | 3q25.33 | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
Description | interleukin 12A |
Gene symbol | IL12B | Synonyms | CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF, NKSF2 | Type of gene | protein-coding |
Chromosome | 5 | Map location | 5q33.3 | dbXrefs | |
Description | interleukin 12B |
GTO ID | GTC0387 |
Trial ID | NCT03281382 |
Disease | Pancreatic Cancer |
Altered gene | E1|IL-12A|IL-12B|yCD|SR39|tk |
Therapeutic/Target gene | Therapeutic gene |
Therapy | DNA oncolytic virus |
Treatment | AdV5-yCD/mutTKSR39rep-hIL12 |
Phase | Phase1 |
Recruitment status | Completed |
Title | PHASE 1 TRIAL OF ONCOLYTIC ADENOVIRUS-MEDIATED CYTOTOXIC AND IL-12 GENE THERAPY IN COMBINATION WITH CHEMOTHERAPY FOR THE TREATMENT OF METASTATIC PANCREATIC CANCER |
Year | 2017 |
Country | United States |
Company sponsor | Henry Ford Health System |
Other ID(s) | 11260 |
Vector information | |||||||||||||
|
Cohort1: dose level 1 | |||||||||||||
|
|||||||||||||
Cohort2: dose level 2 | |||||||||||||
|
|||||||||||||
Cohort3: dose level 3 | |||||||||||||
|